Inventor · disambiguated record
Robert Maclaren
Also filed as: MACLAREN ROBERT · MACLAREN ROBERT E
2 granted patents·22 pending applications·11 citations·filing 2012–2022
57Inventor score
Top patents by PatentIndex Score
24 records- 0182US10836803B2Treatment of retinitis pigmentosaUNIV OXFORD INNOVATION LTD·Filed 2019·Granted Nov 17, 2020·2 cites·15 claims
- 0277US9834788B2AAV -vectors for use in gene therapy of choroideremiaMACLAREN ROBERT·Filed 2012·Granted Dec 5, 2017·9 cites·10 claims
- 0373US2023332176A1Aav-vectors for use in gene therapy of choroideremiaUNIV OXFORD INNOVATION LTD·Filed 2022·Application pending·0 cites
- 0468US2023149566A1Compositions and methods for treating macular dystrophyUNIV OXFORD INNOVATION LTD·Filed 2022·Application pending·0 cites
- 0562US2021130425A1Treatment of retinitis pigmentosaUNIV OXFORD INNOVATION LTD·Filed 2020·Application pending·0 cites
- 0662US2021032656A1Aav-vectors for use in gene therapy of choroideremiaUNIV OXFORD INNOVATION LTD·Filed 2020·Application pending·0 cites
- 0760US2022380831A1Prenylation assayUNIV OXFORD INNOVATION LTD·Filed 2021·Application pending·0 cites
- 0860US2019282658A1Treatment of eye diseaseUNIV OXFORD INNOVATION LTD·Filed 2019·Application pending·0 cites
- 0960US2018360912A1Treatment of eye diseaseUNIV OXFORD INNOVATION LTD·Filed 2018·Application pending·0 cites
- 1057US2020306341A1Treatment of eye diseaseUNIV OXFORD INNOVATION LTD·Filed 2020·Application pending·0 cites
- 1155US2019307900A1Compositions and methods for treating macular dystrophyUNIV OXFORD INNOVATION LTD·Filed 2019·Application pending·0 cites
- 1254US2024191257A1Gene Therapy for Retinal DiseaseUNIV OXFORD INNOVATION LTD·Filed 2022·Application pending·0 cites
- 1353US2018042992A1Treatment of eye diseaseUNIV OXFORD INNOVATION LTD·Filed 2017·Application pending·0 cites
- 1452US2018135078A1Aav-vectors for use in gene therapy of choroideremiaUNIV OXFORD INNOVATION LTD·Filed 2017·Application pending·0 cites
- 1551US2016324921A1Treatment of eye diseaseISIS INNOVATION·Filed 2015·Application pending·0 cites
- 1649US2021147870A1Compositions and methods for the treatment of stargardt diseaseNIGHTSTARX LTD·Filed 2019·Application pending·0 cites
- 1746US2021386871A1Gene therapyUNIV OXFORD INNOVATION LTD·Filed 2019·Application pending·0 cites
- 1845US2018273594A1Treatment of retinitis pigmentosaUNIV OXFORD INNOVATION LTD·Filed 2016·Application pending·0 cites
- 1944US2019017096A1Prenylation assayNIGHTSTARX LTD·Filed 2016·Application pending·0 cites
- 2044US2022249702A1Gene therapy for retinal diseaseUNIV OXFORD INNOVATION LTD·Filed 2019·Application pending·0 cites
- 2141US2020341015A1Prenylation assayNIGHTSTARX LTD·Filed 2018·Application pending·0 cites
- 2233US2016362692A1Treatment of retinitis pigmentosaISIS INNOVATION·Filed 2015·Application pending·0 cites
- 2332US2019309326A1Dual overlapping adeno-associated viral vector system for expressing abca4UNIV OXFORD INNOVATION LTD·Filed 2017·Application pending·0 cites
- 2429US2016206704A1MethodISIS INNOVATION·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Robert Maclaren files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →